Clinical implication of false-positive celiac serology in patients with ileal pouch

Diseases of the Colon and Rectum

Volumn 53, Issue 10, 2010, Pages 1446-1451

  Lian, Lei ^a,b   Remzi, Feza H ^a   Kiran, Ravi P ^a   Fazio, Victor W ^a   Shen, Bo ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Celiac disease; Pouchitis; Restorative proctocolectomy; Serology

Indexed keywords

CIPROFLOXACIN; CORTICOSTEROID; ENDOMYSIUM ANTIBODY; GLIADIN ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOMODULATING AGENT; MESALAZINE; METRONIDAZOLE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FALSE POSITIVE RESULT; FEMALE; HEALTH CENTER; HUMAN; HUMAN TISSUE; ILEITIS; ILEOANAL ANASTOMOSIS; ILEUM POUCH; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RISK; SEROLOGY; SEX; TREATMENT DURATION; ULCERATIVE COLITIS; ANTIBIOTIC RESISTANCE; BLOOD; CELIAC DISEASE; COHORT ANALYSIS; COLON POUCH; LABORATORY DIAGNOSIS; MIDDLE AGED; PREDICTION AND FORECASTING; PROCTOCOLECTOMY; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CELIAC DISEASE; COHORT STUDIES; COLITIS, ULCERATIVE; COLONIC POUCHES; DRUG RESISTANCE, MICROBIAL; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; POUCHITIS; PREDICTIVE VALUE OF TESTS; PROCTOCOLECTOMY, RESTORATIVE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 78049375432     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/DCR.0b013e3181eba46c     Document Type: Article

References (35)

1. Shen B, Remzi FH, Lavery IC, et al. A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy. Clin Gastroenterol Hepatol. 2008;6: 145-158.
2. Shen B, Fazio VW, Remzi FH, et al. Clinical approach to diseases of ileal pouch-anal anastomosis. Am J Gastroenterol. 2005;100: 2796-2807.
3. Shen B, Remzi FH, Lopez AR, et al. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol. 2008;23:26.
4. Shen B, Fazio VW, Remzi FH, et al. Clinical features and quality of life in patients with different phenotypes of Crohn's disease of the ileal pouch. Dis Colon Rectum. 2007;50:1450-1459.
5. Abdelrazeq AS, Kandiyil N, Botterill ID, et al. Predictors for acute and chronic pouchitis following restorative proctocolectomy for ulcerative colitis. Colorectal Dis. 2008;10:805-813.
6. Achkar JP, Al-Haddad M, Lashner B, et al. Differentiating risk factors for acute and chronic pouchitis. Clin GastroenterolHepatol. 2005;3:60-66.
7. Nakamura M, Ikeuchi H, Nakano H, et al. Postoperative joint symptoms: a risk factor for pouchitis in ulcerative colitis patients. Dig Surg. 2006;23:60-64.
8. Simchuk EJ, Thirlby RC. Risk factors andtrue incidence of pouchitis in patients after ileal pouch-anal anastomoses. World JSurg. 2000;24:851-856.
9. Subramani K, Harpaz N, Bilotta J, et al. Refractory pouchitis: does it reflect underlying Crohn's disease? Gut. 1993;34:1539-1542.
10. Shen L, Lian L, Goldblum JR, Remzi FH. Development of de novo celiac disease after restorative proctocolectomy and ileal pouch-anal anastomosis. Inflamm BowelDis. 2009;15:1131-1132.
11. Barton SH, Murray JA. Celiac disease and autoimmunity in the gut and elsewhere. Gastroenterol Clin North Am. 2008;37:411-428.
12. Hadithi M, de Boer H, Meijer JW, et al. Coeliac disease in Dutch patients with Hashimoto's thyroiditis and vice versa. World J Gastroenterol. 2007;13:1715-1722.
13. Luft LM, Barr SG, Martin LO, et al. Autoantibodies to tissue transglutaminase in Sjogren's syndrome and related rheumatic diseases. J Rheumatol. 2003;30:2613-2619.
14. Yang A, Chen Y, Scherl E, et al. Inflammatory bowel disease in patients with celiac disease. Inflamm Bowel Dis. 2005;11:528-532.
15. Shen B, Fazio VW, Remzi FH, et al. Risk factors for diseases of ileal pouch-anal anastomosis in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:81-89. (Pubitemid 43129528)
16. Becker JM, Stucchi AF, Bryant DE. How do you treat refractory pouchitis and when do you decide to remove the pouch? Inflamm Bowel Dis. 1998;4:167-169.
17. Cheifetz A, Itzkowitz S. The diagnosis and treatment ofpouchitis in inflammatory bowel disease. J Clin Gastroenterol. 2004; 38(suppl 1):S44-S50. (Pubitemid 38544543)
18. Meagher AP, Farouk R, Dozois RR, et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long- term outcome in 1310 patients. BrJSurg. 1998;85:800-803.
19. Lohmuller JL, Pemberton JH, Dozois RR, et al. Pouchitis and extraintestinalmanifestations of inflammatory bowel disease after ileal pouchanal anastomosis. Ann Surg. 1990 211:622-627.
20. Hurst RD, Molinari M, Chung TP, et al. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg. 1996;131: 497-500.
21. Sachar DB. 1989 Henry Baker lecture. Inflammatory bowel disease: back to the future. Am J Gastroenterol. 1990;85:373-376.
22. Merrett MN, Soper N, Mortensen N, Jewell DP. Intestinal permeability in the ileal pouch. Gut. 1996;39:226-230.
23. Kroesen AJ, Leistenschneider P, Lehmann K, et al. Increased bacterial permeation in long-lasting ileoanal pouches. Inflamm Bowel Dis. 2006;12:736-744.
24. Barker JM, Liu E. Celiac disease: pathophysiology, clinical manifestations, and associated autoimmune conditions. Adv Pediatr. 2008;55:349-365.
25. Sjöberg K, Lindgren S, Eriksson S. Frequent occurrence of nonspecific gliadin antibodies in chronic liver disease: endomysial but not gliadin antibodies predict coeliac disease in patients with chronic liver disease. Scand J Gastroenterol. 1997;32:1162-1167.
26. Shen B, Remzi FH, Nutter B, et al. Association between immune-associated disorders and adverse outcomes of ileal pouchanal anastomosis. Am J Gastroenterol. 2009;104:655-664.
27. Sandborn WJ, Pardi DS. Clinical management of pouchitis. Gastroenterology. 2004;127:1809-1814.
28. Calabrese C, Gionchetti P, Rizzello F, et al. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment Pharmacol Ther. 2008;27:759-764.
29. Bizzaro N, Villalta D, Tonutti E, et al. IgA and IgG tissue transglutaminase antibody prevalence and clinical significance in connective tissue diseases, inflammatory bowel disease, and primary biliary cirrhosis. Dig Dis Sci. 2003;48:2360-2365.
30. Barker JM, Yu J, Yu L, et al. Autoantibody "sub-specificity" in type 1 diabetes: risk for organ specific autoimmunity clusters in distinct groups. Diabetes Care. 2005;28:850-855.
31. AGA institute medical position statement on the diagnosis and management of celiac disease. Gastroenterology. 2006;131:1977-1980.
32. Leeds JS, Höroldt BS, Sidhu R, et al. Is there an association between coeliac disease and inflammatory bowel diseases? A study of relative prevalence in comparison with population controls. Scand J Gastroenterol. 2007;42:1214-1220.
33. Wapenaar MC, Monsuur AJ, van Bodegraven AA, et al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut. 2008;57:463-467.
34. Maple JT, Pearson RK, Murray JA, et al. Silent celiac disease activated by pancreaticoduodenectomy. Dig Dis Sci. 2007;52: 2140-2144.
35. Bai J, Moran C, Martinez C, et al. Celiac sprue after surgery of the upper gastrointestinal tract: report of 10 patients with special attention to diagnosis, clinical behavior, and follow-up. J Clin Gastroenterol. 1991;13:521-524.